Convergence of nanotechnology with radiation therapy-insights and implications for clinical translation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chatterjee, Dev Kumar | - |
dc.contributor.author | Wolfe, Tatiana | - |
dc.contributor.author | Lee, Jihyoun | - |
dc.contributor.author | Brown, Aaron P. | - |
dc.contributor.author | Singh, Pankaj Kumar | - |
dc.contributor.author | Bhattarai, Shanta Raj | - |
dc.contributor.author | Diagaradjane, Parmeswaran | - |
dc.contributor.author | Krishnan, Sunil | - |
dc.date.accessioned | 2021-08-12T01:12:36Z | - |
dc.date.available | 2021-08-12T01:12:36Z | - |
dc.date.issued | 2013-08 | - |
dc.identifier.issn | 2218-676X | - |
dc.identifier.issn | 2219-6803 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13499 | - |
dc.description.abstract | Improvements in accuracy and efficacy in treating tumors with radiation therapy (RT) over the years have been fueled by parallel technological and conceptual advances in imaging and image-guidance techniques, radiation treatment machines, computational methods, and the understanding of the biology of tumor response to RT. Recent advances in our understanding of the hallmarks of cancer and the emergence of strategies to combat these traits of cancer have resulted in an expanding repertoire of targeted therapeutics, many of which can be exploited for enhancing the efficacy of RT. Complementing this advent of new treatment options is the evolution of our knowledge of the interaction between nanoscale materials and human tissues (nanomedicine). As with the changes in RT paradigms when the field has encountered newer and maturing disciplines, the incorporation of nanotechnology innovations into radiation oncology has the potential to refine or redefine its principles and revolutionize its practice. This review provides a summary of the principles, applications, challenges and outlook for the use of metallic nanoparticles in RT. | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | AME Publishing Company | - |
dc.title | Convergence of nanotechnology with radiation therapy-insights and implications for clinical translation | - |
dc.type | Article | - |
dc.publisher.location | 중국 | - |
dc.identifier.doi | 10.3978/j.issn.2218-676X.2013.08.10 | - |
dc.identifier.wosid | 000209643200004 | - |
dc.identifier.bibliographicCitation | Translational Cancer Research, v.2, no.4, pp 256 - 268 | - |
dc.citation.title | Translational Cancer Research | - |
dc.citation.volume | 2 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 256 | - |
dc.citation.endPage | 268 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | GOLD NANOPARTICLE RADIOSENSITIZATION | - |
dc.subject.keywordPlus | LOADED PLLA NANOPARTICLES | - |
dc.subject.keywordPlus | NEUTRON-CAPTURE THERAPY | - |
dc.subject.keywordPlus | MAGNETIC NANOPARTICLES | - |
dc.subject.keywordPlus | DOSE ENHANCEMENT | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | HYPERTHERMIA | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | RADIOIMMUNOTHERAPY | - |
dc.subject.keywordPlus | RADIOPROTECTION | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | nanoparticles | - |
dc.subject.keywordAuthor | nanotechnology | - |
dc.subject.keywordAuthor | radiation therapy (RT) | - |
dc.subject.keywordAuthor | review | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.